Pasar al contenido principal

BUSQUEDA DE NUEVOS ANTIVIRALES DE AMPLIO ESPECTRO: TRANSPORTE DE LIPIDOS Y PROTEINAS MITOCONDRIALES COMO DIANAS

RTI2018-094445-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

β-Cyclodextrins as affordable antivirals to treat coronavirus infection

  • Raïch-Regué, Dalia
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Tarrés Freixas, Ferran
  • Sachse, Martin
  • Perez-Zsol, Daniel
  • Muñoz Basagoiti, Jordana
  • Fernández-Sánchez, Sara Y.
  • Gallemí, Marçal
  • Ortega-González, Paula
  • Fernández-Oliva, Alberto
  • Gabaldón, José A.
  • Nuñez-Delicado, Estrella
  • Casas, Josefina
  • Roca, Núria
  • Cantero, Guillermo
  • Pérez, Mónica
  • Usai, Carla
  • Lorca-Oró, Cristina
  • Serra Gironella, Joan
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Blanco, Julià
  • Clotet Sala, Bonaventura
  • Cerón-Carrasco, José P.
  • Izquierdo-Useros, Nuria
  • Risco, Cristina
The SARS-CoV-2 pandemic made evident that there are only a few drugs against coronavirus. Here we aimed to identify a cost-effective antiviral with broad spectrum activity and high safety profile. Starting from a list of 116 drug candidates, we used molecular modelling tools to rank the 44 most promising inhibitors. Next, we tested their efficacy as antivirals against α and β coronaviruses, such as the HCoV-229E and SARS-CoV-2 variants. Four drugs, OSW-1, U18666A, hydroxypropyl-β-cyclodextrin (HβCD) and phytol, showed in vitro antiviral activity against HCoV-229E and SARS-CoV-2. The mechanism of action of these compounds was studied by transmission electron microscopy and by fusion assays measuring SARS-CoV-2 pseudoviral entry into target cells. Entry was inhibited by HβCD and U18666A, yet only HβCD inhibited SARS-CoV-2 replication in the pulmonary Calu-3 cells. Compared to the other cyclodextrins, β-cyclodextrins were the most potent inhibitors, which interfered with viral fusion via cholesterol depletion. β-cyclodextrins also prevented infection in a human nasal epithelium model ex vivo and had a prophylactic effect in the nasal epithelium of hamsters in vivo. All accumulated data point to β-cyclodextrins as promising broad-spectrum antivirals against different SARS-CoV-2 variants and distant alphacoronaviruses. Given the wide use of β-cyclodextrins for drug encapsulation and their high safety profile in humans, our results support their clinical testing as prophylactic antivirals., This work has been funded by grant RTI2018-094445-B100 (MCIU/AEI/FEDER, UE) from the Ministry of Science and Innovation of Spain (C.R.), by Palex Medical S.A., Sika S.A.U. and 7 more companies, and by Ms. Raquel Casaus Alvarez, Mr. Miguel Pardo Gil, Mr. Jacques Noguès and a total of 2916 citizens through the Precipita crowdfunding platform of Fecyt (Fundación Española para la Ciencia y la Tecnología). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) and by institutional funding of Grifols, Pharma Mar, HIPRA, Amassence and Palobiofarma. This work used the computational resources of the Centro de Supercomputación de Galicia (CESGA) supported by the Partnership for Advanced Computing in Europe (PRACE) COVID-19 Fast Track Call for Proposals – Allocation Decision – Proposal COVID19-85., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis

  • Sachse, Martin
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Raïch-Regué, Dàlia
  • Rodon, Jordi
  • Losada, Alejandro
  • Avilés, Pablo
  • Cuevas, Carmen
  • Paredes, Roger
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Serra Gironella, Joan
  • Izquierdo-Useros, Nuria
  • Risco, Cristina
The pandemic caused by the new coronavirus SARS-CoV-2 has made evident the need for broad-spectrum, efficient antiviral treatments to combat emerging and re-emerging viruses. Plitidepsin is an antitumor agent of marine origin that has also shown a potent pre-clinical efficacy against SARS-CoV-2. Plitidepsin targets the host protein eEF1A (eukaryotic translation elongation factor 1 alpha) and affects viral infection at an early, post-entry step. Because electron microscopy is a valuable tool to study virus-cell interactions and the mechanism of action of antiviral drugs, in this work we have used transmission electron microscopy (TEM) to evaluate the effects of plitidepsin in SARS-CoV-2 infection in cultured Vero E6 cells 24 and 48h post-infection. In the absence of plitidepsin, TEM morphological analysis showed double-membrane vesicles (DMVs), organelles that support coronavirus genome replication, single-membrane vesicles with viral particles, large vacuoles with groups of viruses and numerous extracellular virions attached to the plasma membrane. When treated with plitidepsin, no viral structures were found in SARS-CoV-2-infected Vero E6 cells. Immunogold detection of SARS-CoV-2 nucleocapsid (N) protein and double-stranded RNA (dsRNA) provided clear signals in cells infected in the absence of plitidepsin, but complete absence in cells infected and treated with plitidepsin. The present study shows that plitidepsin blocks the biogenesis of viral replication organelles and the morphogenesis of virus progeny. Electron microscopy morphological analysis coupled to immunogold labeling of SARS-CoV-2 products offers a unique approach to understand how antivirals such as plitidepsin work., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Middle East respiratory coronavirus (MERS-CoV) internalized by llama alveolar macrophages does not result in virus replication or induction of pro-inflammatory cytokines

  • Rodon, Jordi
  • Sachse, Martin
  • Te, Nigeer
  • Segalés, Joaquim
  • Bensaid, Albert
  • Risco, Cristina
  • Serra Gironella, Joan
Severe Middle East respiratory syndrome (MERS) is characterized by massive infiltration of immune cells in lungs. MERS-coronavirus (MERS-CoV) replicates in vitro in human macrophages, inducing high proinflammatory responses. In contrast, camelids, the main reservoir for MERS-CoV, are asymptomatic carriers. Although limited infiltration of leukocytes has been observed in the lower respiratory tract of camelids, their role during infection remains unknown. Here we studied whether llama alveolar macrophages (LAMs) are susceptible to MERS-CoV infection and can elicit pro-inflammatory responses. MERS-CoV did not replicate in LAMs; however, they effectively capture and degrade viral particles. Moreover, transcriptomic analyses showed that LAMs do not induce pro-inflammatory cytokines upon MERS-CoV sensing., This study was performed as part of the Zoonotic Anticipation and Preparedness Initiative (ZAPI project) [Innovative Medicines initiative (IMI) grant 115760] and the VetBioNet project (EU Grant Agreement INFRA-2016-1 Nº731014), with assistance and financial support from IMI and the European Commission and contributions from EFPIA partners and from grant RTI2018-09445-B-100 from the Ministry of Science and Innovation of Spain (to C.R.). J.R. was partially supported by the VetBioNet project. IRTA is supported by CERCA Programme/Generalitat de Catalunya., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells

  • Perez-Zsolt, Daniel
  • Muñoz-Basagoiti, Jordana
  • Rodón, Jordi
  • Elosua-Bayes, Marc
  • Raïch-Regué, Dàlia
  • Risco, Cristina
  • Sachse, Martín
  • Pino, María
  • Gumber, Sanjeev
  • Paiardini, Mirko
  • Chojnacki, Jakub
  • Erkizia, tziar
  • Muñiz-Trabudua, Xabier
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Noguera, Marc
  • Paredes, Roger
  • Trinité, Benjamin
  • Tarrés-Freixas, Ferrán
  • Blanco, Ignacio
  • Guallar, Victor
  • Carrillo, Jorge
  • Blanco, Julià
  • Telenti, Amalio
  • Heyn, Holger
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Martínez-Picado, Javier
  • Vergara-Alert, Júlia
  • Izquierdo-Useros, Núria
Antigen-presenting cells (APCs) may be resistant to SARS-CoV-2 infection but still contribute to viral pathogenesis. Lectins such as sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169) mediate the attachment of viruses to APCs. Here, we show that APCs effectively capture SARS-CoV-2 within compartments via recognition of Siglec-1. This receptor interacts with sialylated gangliosides on membranes of SARS-CoV-2 variants, as previously shown for retroviruses or filoviruses [1]. Blockage of Siglec-1 on monocyte-derived dendritic cells (MDDCs) decreased SARS-CoV-2 viral transfer or trans-infection to bystander target cells. However, monocyte-derived macrophages (MDMs) capturing SARS-CoV-2 via Siglec-1 did not transmit infectious particles. The presence of pulmonary APCs co-expressing Siglec-1 and SARS-CoV-2 corroborated these findings in vivo., The research of the CBIG consortium (constituted by IRTA-CReSA, BSC, & IrsiCaixa) is supported by Grifols Pharmaceutical. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). N.I.-U. is supported by the grant PID2020-117145RB-I00 from the Spanish Ministry of Science and Innovation. J.M.-P. is supported by the grant PID2019-109870RB-I00 from the Spanish Ministry of Science and Innovation and in part also by Grifols. The C.R. laboratory is funded by RTI2018-094445-B100 (MCIU/AEI/FEDER, UE). The NHP study was primarily supported by a YNPRC Coronavirus Pilot Research Project Program grant to M.Pa. under award P51 OD11132, Emergent Venture Fast grant program to M.Pa. under awards #2206 and #2144, and William and Lula Pitts Foundation (to M.Pa.). X.M.-T. is supported by the Spanish Ministry of Science and Innovation and the European Regional Development Fund under agreement BES-2017-082900., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis

  • Sachse, Martín
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Raïch-Regué, Dàlia
  • Rodón, Jordi
  • Losada, Alejandro
  • Avilés, Pablo
  • Cuevas, Carmen
  • Paredes, Roger
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Vergara-Alert, Júlia
  • Izquierdo-Useros, Núria
  • Risco, Cristina
The pandemic caused by the new coronavirus SARS-CoV-2 has made evident the need for broad-spectrum, efficient antiviral treatments to combat emerging and re-emerging viruses. Plitidepsin is an antitumor agent of marine origin that has also shown a potent pre-clinical efficacy against SARS-CoV-2. Plitidepsin targets the host protein eEF1A (eukaryotic translation factor 1 alpha 1) and affects viral infection at an early, post-entry step. Because electron microscopy is a valuable tool to study virus-cell interactions and the mechanism of action of antiviral drugs, in this work we have used transmission electron microscopy (TEM) to evaluate the effects of plitidepsin in SARS-CoV-2 infection in cultured Vero E6 cells 24 and 48h post-infection. In the absence of plitidepsin, TEM morphological analysis showed double-membrane vesicles (DMVs), organelles that support coronavirus genome replication, single-membrane vesicles with viral particles, large vacuoles with groups of viruses and numerous extracellular virions attached to the plasma membrane. When treated with plitidepsin, no viral structures were found in SARS-CoV-2-infected Vero E6 cells. Immunogold detection of SARS-CoV-2 nucleocapsid (N) protein and double-stranded RNA (dsRNA) provided clear signals in cells infected in the absence of plitidepsin, but complete absence in cells infected and treated with plitidepsin. The present study shows that plitidepsin completely blocks the biogenesis of viral replication organelles and the morphogenesis of virus progeny. Electron microscopy morphological analysis coupled to immunogold labeling of SARS-CoV-2 products offers a unique approach to understand how antivirals such as plitidepsin work., This research was funded by Pharma Mar, which commercializes Aplidin/Plitidepsin. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). N.I-U. is supported by grant PID2020-117145RB-I00 from the Spanish Ministry of Science and Innovation. C.R. is supported by grant RTI2018-094445-B-I00 (MCI/AEI/FEDER, UE) from the Spanish Ministry of Science and Innovation, No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis

  • Sachse, Martín
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Raïch-Regué, Dàlia
  • Rodón, Jordi
  • Losada, Alejandro
  • Avilés, Pablo
  • Cuevas, Carmen
  • Paredes, Roger
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Vergara-Alert, Júlia
  • Izquierdo-Useros, Núria
  • Risco, Cristina
The pandemic caused by the new coronavirus SARS-CoV-2 has made evident the need for broad-spectrum, efficient antiviral treatments to combat emerging and re-emerging viruses. Plitidepsin is an antitumor agent of marine origin that has also shown a potent pre-clinical efficacy against SARS-CoV-2. Plitidepsin targets the host protein eEF1A (eukaryotic translation elongation factor 1 alpha) and affects viral infection at an early, post-entry step. Because electron microscopy is a valuable tool to study virus-cell interactions and the mechanism of action of antiviral drugs, in this work we have used transmission electron microscopy (TEM) to evaluate the effects of plitidepsin in SARS-CoV-2 infection in cultured Vero E6 cells 24 and 48h post-infection. In the absence of plitidepsin, TEM morphological analysis showed double-membrane vesicles (DMVs), organelles that support coronavirus genome replication, single-membrane vesicles with viral particles, large vacuoles with groups of viruses and numerous extracellular virions attached to the plasma membrane. When treated with plitidepsin, no viral structures were found in SARS-CoV-2-infected Vero E6 cells. Immunogold detection of SARS-CoV-2 nucleocapsid (N) protein and double-stranded RNA (dsRNA) provided clear signals in cells infected in the absence of plitidepsin, but complete absence in cells infected and treated with plitidepsin. The present study shows that plitidepsin blocks the biogenesis of viral replication organelles and the morphogenesis of virus progeny. Electron microscopy morphological analysis coupled to immunogold labeling of SARS-CoV-2 products offers a unique approach to understand how antivirals such as plitidepsin work., This research was funded by Pharma Mar, which commercializes Aplidin/Plitidepsin. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com) and the CBIG consortium supported by Grifols. N.I–U. is supported by grant PID2020-117145RB-I00 from the Spanish Ministry of Science and Innovation. C.R. is supported by grant RTI2018-094445-B-I00 (MCI/AEI/FEDER, UE) from the Spanish Ministry of Science and Innovation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Beta-Cyclodextrins as affordable antivirals to treat coronavirus infection

  • Raïch-Regué, Dàlia
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Perez-Zsolt, Daniel
  • Muñoz-Basagoiti, Jordana
  • Sachse, Martín
  • Fernández-Sánchez, Sara Yolanda
  • Gallemí, Marçal
  • Ortega-González, Paula
  • Fernández-Oliva, Alberto
  • Gabaldón, José A.
  • Núñez-Delicado, Estrella
  • Casas, Josefina
  • Tarrés-Freixas, Ferrán
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Blanco, Julià
  • Clotet, Bonaventura
  • Cerón-Carrasco, José P.
  • Izquierdo-Useros, Núria
  • Risco, Cristina
The SARS-CoV-2 pandemic made evident that we count with few coronavirus-fighting drugs. Here we aimed to identify a cost-effective antiviral with broad spectrum activity and high safety and tolerability profiles. We began elaborating a list of 116 drugs previously used to treat other pathologies or characterized in pre-clinical studies with potential to treat coronavirus infections. We next employed molecular modelling tools to rank the 44 most promising inhibitors and tested their efficacy as antivirals against a panel of alpha and beta coronavirus, e.g., the HCoV-229E and SARS-CoV-2 viruses. Four drugs, OSW-1, U18666A, hydroxypropyl-beta-cyclodextrin (HbetaCD) and phytol, showed antiviral activity against both HCoV-229E (in MRC5 cells) and SARS-CoV-2 (in Vero E6 cells). The mechanism of action of these compounds was studied by transmission electron microscopy (TEM) and by testing their capacity to inhibit the entry of SARS-CoV-2 pseudoviruses in ACE2-expressing HEK-293T cells. The entry was inhibited by HbetaCD and U18666A, yet only HbetaCD could inhibit SARS-CoV-2 replication in the pulmonary cells Calu-3. With these results and given that cyclodextrins are widely used for drug encapsulation and can be safely administered to humans, we further tested 6 native and modified cyclodextrins, which confirmed β-cyclodextrins as the most potent inhibitors of SARS-CoV-2 replication in Calu-3 cells. All accumulated data points to beta-cyclodextrins as promising candidates to be used in the therapeutic treatments for SARS-CoV-2 and possibly other respiratory viruses., This work has been funded by grant RTI2018-094445-B100 (MCIU/AEI/FEDER, UE) from the Ministry of Science and Innovation of Spain (C.R.), by Palex Medical S.A., Sika S.A.U. and 7 more companies, and by Ms. Raquel Casaus Alvarez, Mr. Miguel Pardo Gil, Mr. Jacques Noguès and a total of 2,916 citizens through the Precipita crowdfunding platform of Fecyt (Fundación Española para la Ciencia y la Tecnología). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) and by institutional funding of Grifols, Pharma Mar, HIPRA, Amassence and Palobiofarma. This work used the computational resources of the Centro de Supercomputación de Galicia (CESGA) supported by the Partnership for Advanced Computing in Europe (PRACE) COVID-19 Fast Track Call for Proposals – Allocation Decision – Proposal COVID19-85., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antiviral Activity of Acetylsalicylic Acid against Bunyamwera Virus in Cell Culture

  • Fernández-Sánchez, Sara Yolanda
  • Cerón-Carrasco, José P.
  • Risco, Cristina
  • Fernández de Castro, Isabel
The Bunyavirales order is a large group of RNA viruses that includes important pathogens for humans, animals and plants. With high-throughput screening of clinically tested compounds we have looked for potential inhibitors of the endonuclease domain of a bunyavirus RNA polymerase. From a list of fifteen top candidates, five compounds were selected and their antiviral properties studied with Bunyamwera virus (BUNV), a prototypic bunyavirus widely used for studies about the biology of this group of viruses and to test antivirals. Four compounds (silibinin A, myricetin, L-phenylalanine and p-aminohippuric acid) showed no antiviral activity in BUNV-infected Vero cells. On the contrary, acetylsalicylic acid (ASA) efficiently inhibited BUNV infection with a half maximal inhibitory concentration (IC50) of 2.02 mM. In cell culture supernatants, ASA reduced viral titer up to three logarithmic units. A significant dose-dependent reduction of the expression levels of Gc and N viral proteins was also measured. Immunofluorescence and confocal microscopy showed that ASA protects the Golgi complex from the characteristic BUNV-induced fragmentation in Vero cells. Electron microscopy showed that ASA inhibits the assembly of Golgi-associated BUNV spherules that are the replication organelles of bunyaviruses. As a consequence, the assembly of new viral particles is also significantly reduced. Considering its availability and low cost, the potential usability of ASA to treat bunyavirus infections deserves further investigation., This research was funded by the Spanish Ministry of Science and Innovation [RTI2018-094445-B-I00. MCI/AEI/FEDER, UE]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Molecular mapping of virus-infected cells with immunogold and metal-tagging transmission electron microscopy

  • Sachse, Martín
  • Fernández de Castro, Isabel
  • Tenorio, Raquel
  • Risco, Cristina
Transmission electron microscopy (TEM) has been essential to study virus-cell interactions. The architecture of viral replication factories, the principles of virus assembly and the components of virus egress pathways are known thanks to the contribution of TEM methods. Specially, when studying viruses in cells, methodologies for labeling proteins and other macromolecules are important tools to correlate morphology with function. In this review, we present the most widely used labeling method for TEM, immunogold, together with a lesser known technique, metal-tagging transmission electron microscopy (METTEM) and how they can contribute to study viral infections. Immunogold uses the power of antibodies and electron dense, colloidal gold particles while METTEM uses metallothionein (MT), a metal-binding protein as a clonable tag. MT molecules build gold nano-clusters inside cells when these are incubated with gold salts. We describe the necessary controls to confirm that signals are specific, the advantages and limitations of both methods, and show some examples of immunogold and METTEM of cells infected with viruses., This work has been funded by grant RTI2018-094445-B100 (MCIU/AEI/FEDER, UE) from the Ministry of Science and Innovation of Spain (C.R.). We are grateful to Ms. Sara Y. Fernández-Sánchez for critically reading the manuscript. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Imaging Bunyavirus Infections by Transmission Electron Microscopy: Conventional Sample Preparation vs High-Pressure Freezing and Freeze-Substitution

  • Sachse, Martín
  • Fernández-Sánchez, Sara Yolanda
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Risco, Cristina
Transmission electron microscopy significantly contributed to unveil the course of virus entry, replication, morphogenesis, and egress. For these studies, the most widely used approach is imaging ultrathin sections of virus-infected cells embedded in a plastic resin that is transparent to electrons. Before infiltration in a resin, cells must be processed to stabilize their components under the observation conditions in an electron microscope, such as high vacuum and irradiation with electrons. For conventional sample preparation, chemical fixation and dehydration are followed by infiltration in the resin and polymerization to produce a hard block that can be sectioned with an ultramicrotome. Another method that provides a superior preservation of cell components is high-pressure freezing (HPF) followed by freeze substitution (FS) before resin infiltration and polymerization. This chapter describes both procedures with cells infected with Bunyamwera virus (BUNV), a well characterized member of the Bunyavirales, and compares the morphological details of different viral structures imaged in the two types of samples. Advantages, disadvantages, and applications of conventional processing and HPF/FS are also presented and discussed., This research was supported by grant RTI2018-094445-B100 (MCI/AEI/FEDER, EU) from the Spanish Ministry of Science and Innovation (C.R.)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Middle East respiratory coronavirus (MERS-CoV) internalized by llama alveolar macrophages does not result in virus replication or induction of pro-inflammatory cytokines

  • Rodon, Jordi
  • Sachse, Martin
  • Te, Nigeer
  • Segalés, Joaquim
  • Bensaid, Albert
  • Risco, Cristina
  • Serra Gironella, Joan
Severe Middle East respiratory syndrome (MERS) is characterized by massive infiltration of immune cells in lungs. MERS-coronavirus (MERS-CoV) replicates in vitro in human macrophages, inducing high proinflammatory responses. In contrast, camelids, the main reservoir for MERS-CoV, are asymptomatic carriers. Although limited infiltration of leukocytes has been observed in the lower respiratory tract of camelids, their role during infection remains unknown. Here we studied whether llama alveolar macrophages (LAMs) are susceptible to MERS-CoV infection and can elicit pro-inflammatory responses. MERS-CoV did not replicate in LAMs; however, they effectively capture and degrade viral particles. Moreover, transcriptomic analyses showed that LAMs do not induce pro-inflammatory cytokines upon MERS-CoV sensing., This study was performed as part of the Zoonotic Anticipation and Preparedness Initiative (ZAPI project) [Innovative Medicines initiative (IMI) grant 115760] and the VetBioNet project (EU Grant Agreement INFRA-2016-1 Nº731014), with assistance and financial support from IMI and the European Commission and contributions from EFPIA partners and from grant RTI2018-09445-B-100 from the Ministry of Science and Innovation of Spain (to C.R.). J.R. was partially supported by the VetBioNet project. IRTA is supported by CERCA Programme/Generalitat de Catalunya., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis

  • Sachse, Martin
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Raïch-Regué, Dàlia
  • Rodon, Jordi
  • Losada, Alejandro
  • Avilés, Pablo
  • Cuevas, Carmen
  • Paredes, Roger
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Serra Gironella, Joan
  • Izquierdo-Useros, Nuria
  • Risco, Cristina
The pandemic caused by the new coronavirus SARS-CoV-2 has made evident the need for broad-spectrum, efficient antiviral treatments to combat emerging and re-emerging viruses. Plitidepsin is an antitumor agent of marine origin that has also shown a potent pre-clinical efficacy against SARS-CoV-2. Plitidepsin targets the host protein eEF1A (eukaryotic translation elongation factor 1 alpha) and affects viral infection at an early, post-entry step. Because electron microscopy is a valuable tool to study virus-cell interactions and the mechanism of action of antiviral drugs, in this work we have used transmission electron microscopy (TEM) to evaluate the effects of plitidepsin in SARS-CoV-2 infection in cultured Vero E6 cells 24 and 48h post-infection. In the absence of plitidepsin, TEM morphological analysis showed double-membrane vesicles (DMVs), organelles that support coronavirus genome replication, single-membrane vesicles with viral particles, large vacuoles with groups of viruses and numerous extracellular virions attached to the plasma membrane. When treated with plitidepsin, no viral structures were found in SARS-CoV-2-infected Vero E6 cells. Immunogold detection of SARS-CoV-2 nucleocapsid (N) protein and double-stranded RNA (dsRNA) provided clear signals in cells infected in the absence of plitidepsin, but complete absence in cells infected and treated with plitidepsin. The present study shows that plitidepsin blocks the biogenesis of viral replication organelles and the morphogenesis of virus progeny. Electron microscopy morphological analysis coupled to immunogold labeling of SARS-CoV-2 products offers a unique approach to understand how antivirals such as plitidepsin work., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

β-Cyclodextrins as affordable antivirals to treat coronavirus infection

  • Raïch-Regué, Dalia
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Tarrés Freixas, Ferran
  • Sachse, Martin
  • Perez-Zsol, Daniel
  • Muñoz Basagoiti, Jordana
  • Fernández-Sánchez, Sara Y.
  • Gallemí, Marçal
  • Ortega-González, Paula
  • Fernández-Oliva, Alberto
  • Gabaldón, José A.
  • Nuñez-Delicado, Estrella
  • Casas, Josefina
  • Roca, Núria
  • Cantero, Guillermo
  • Pérez, Mónica
  • Usai, Carla
  • Lorca-Oró, Cristina
  • Serra Gironella, Joan
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Blanco, Julià
  • Clotet Sala, Bonaventura
  • Cerón-Carrasco, José P.
  • Izquierdo-Useros, Nuria
  • Risco, Cristina
The SARS-CoV-2 pandemic made evident that there are only a few drugs against coronavirus. Here we aimed to identify a cost-effective antiviral with broad spectrum activity and high safety profile. Starting from a list of 116 drug candidates, we used molecular modelling tools to rank the 44 most promising inhibitors. Next, we tested their efficacy as antivirals against α and β coronaviruses, such as the HCoV-229E and SARS-CoV-2 variants. Four drugs, OSW-1, U18666A, hydroxypropyl-β-cyclodextrin (HβCD) and phytol, showed in vitro antiviral activity against HCoV-229E and SARS-CoV-2. The mechanism of action of these compounds was studied by transmission electron microscopy and by fusion assays measuring SARS-CoV-2 pseudoviral entry into target cells. Entry was inhibited by HβCD and U18666A, yet only HβCD inhibited SARS-CoV-2 replication in the pulmonary Calu-3 cells. Compared to the other cyclodextrins, β-cyclodextrins were the most potent inhibitors, which interfered with viral fusion via cholesterol depletion. β-cyclodextrins also prevented infection in a human nasal epithelium model ex vivo and had a prophylactic effect in the nasal epithelium of hamsters in vivo. All accumulated data point to β-cyclodextrins as promising broad-spectrum antivirals against different SARS-CoV-2 variants and distant alphacoronaviruses. Given the wide use of β-cyclodextrins for drug encapsulation and their high safety profile in humans, our results support their clinical testing as prophylactic antivirals., This work has been funded by grant RTI2018-094445-B100 (MCIU/AEI/FEDER, UE) from the Ministry of Science and Innovation of Spain (C.R.), by Palex Medical S.A., Sika S.A.U. and 7 more companies, and by Ms. Raquel Casaus Alvarez, Mr. Miguel Pardo Gil, Mr. Jacques Noguès and a total of 2916 citizens through the Precipita crowdfunding platform of Fecyt (Fundación Española para la Ciencia y la Tecnología). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) and by institutional funding of Grifols, Pharma Mar, HIPRA, Amassence and Palobiofarma. This work used the computational resources of the Centro de Supercomputación de Galicia (CESGA) supported by the Partnership for Advanced Computing in Europe (PRACE) COVID-19 Fast Track Call for Proposals – Allocation Decision – Proposal COVID19-85., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 interaction with Siglec-1 mediates trans -infection by dendritic cells

  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Rodon, Jordi|||0000-0002-1032-9091
  • Elosua-Bayes, Marc|||0000-0001-5315-815X
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Risco, Cristina|||0000-0001-7501-5934
  • Sachse, Martin
  • Pino, Maria
  • Gumber, Sanjeev
  • Paiardini, Mirko|||0000-0002-7276-3600
  • Chojnacki, Jakub|||0000-0002-4457-8096
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Muñiz-Trabudua, Xabier|||0000-0002-1142-4381
  • Ballana, Ester|||0000-0002-5215-7363
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Paredes, Roger|||0000-0002-6553-691X
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Guallar, Victor|||0000-0002-4580-1114
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
  • Telenti, Amalio
  • Heyn, Holger|||0000-0002-3276-1889
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis

  • Sachse, Martin
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Rodon, Jordi|||0000-0002-1032-9091
  • Losada, Alejandro
  • Avilés, Pablo
  • Cuevas, Carmen
  • Paredes, Roger|||0000-0002-6553-691X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Risco, Cristina|||0000-0001-7501-5934
The pandemic caused by the new coronavirus SARS-CoV-2 has made evident the need for broad-spectrum, efficient antiviral treatments to combat emerging and re-emerging viruses. Plitidepsin is an antitumor agent of marine origin that has also shown a potent pre-clinical efficacy against SARS-CoV-2. Plitidepsin targets the host protein eEF1A (eukaryotic translation elongation factor 1 alpha) and affects viral infection at an early, post-entry step. Because electron microscopy is a valuable tool to study virus-cell interactions and the mechanism of action of antiviral drugs, in this work we have used transmission electron microscopy (TEM) to evaluate the effects of plitidepsin in SARS-CoV-2 infection in cultured Vero E6 cells 24 and 48h post-infection. In the absence of plitidepsin, TEM morphological analysis showed double-membrane vesicles (DMVs), organelles that support coronavirus genome replication, single-membrane vesicles with viral particles, large vacuoles with groups of viruses and numerous extracellular virions attached to the plasma membrane. When treated with plitidepsin, no viral structures were found in SARS-CoV-2-infected Vero E6 cells. Immunogold detection of SARS-CoV-2 nucleocapsid (N) protein and double-stranded RNA (dsRNA) provided clear signals in cells infected in the absence of plitidepsin, but complete absence in cells infected and treated with plitidepsin. The present study shows that plitidepsin blocks the biogenesis of viral replication organelles and the morphogenesis of virus progeny. Electron microscopy morphological analysis coupled to immunogold labeling of SARS-CoV-2 products offers a unique approach to understand how antivirals such as plitidepsin work.